CTNNB1 and neoplasm: We further explored the cell type composition across the 18 samples by grouping our samples according to tissue entity (CPA, EIA or NAG) and mutational status—available from previous next‐generation DNA or Sanger sequencing of bulk tumour tissues (no known driver mutation, CTNNB1 mutations, and PRKACA/GNAS mutations) (Figure 6D).